Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.

Inclusion Criteria:

\-

Patients enrolled must meet the following criteria:

1. ≥18 years old and ≤70 years old, male or female;
2. Patients with haploid peripheral blood stem cell transplantation of AML;
3. All patients received BU based myeloablative conditionings;
4. A diagnosis of high-risk AML is one of the following:

   ① Patients without morphologic CR before transplantation, including patients with initial refractory disease and recurrence.

   ② AML with poor prognosis (Standardized diagnosis and prognostic stratification of acute myeloid leukemia based on ELN edition which was 2022 Year) .
5. Blood routine: neutrophils ≥1×10\^9/L, platelet ≥50.0×10\^9/L;
6. There is no active grade II or higher acute GVHD or moderate or severe chronic GVHD;
7. The ECOG score is 0 to 2;
8. Donor lymphocytes are available;
9. The patient must be able to understand and be willing to participate in the study and sign an informed consent form.

Exclusion Criteria:

* Possible subjects who meet any of the following criteria will be excluded from the trial:

  1. Those who are allergic to known azacitidine or interferon
  2. Patients with active acute GVHD;
  3. Patients with moderate or more chronic GVHD;
  4. Non-haploid donor transplants;
  5. Patients who have not achieved complete remission after transplantation;
  6. AML recurrence after transplantation (bone marrow, peripheral blood primitive cells ≥5% or extramedullary recurrence), or graft rejection, bone marrow donor cell chimeric rate (STR) \<90%;
  7. Patient blood routine: ANC\<1.0×10\^9/L or PLT\<50×10\^9/L;
  8. Combined with severe organ dysfunction:liver function (AST/ALT) \>3 times normal upper limit; the direct bilirubin \> 3 times normal upper limit; renal function (Cr) \< 50mL/min or \>1.5 times normal upper limit, regardless of hemodialysis treatment;
  9. Patient with severe active infection;
  10. Pregnant or lactating women;
  11. Have received other interventions or are receiving other research drugs before the study begins;
  12. At the discretion of the investigator, other dangerous complications may result.